The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to terms with the fact that it may not be able to repeat its success.
Inside the halls of #ASCO2025 (Max Gelman for Endpoints News)
May 27, 2026 09:53 AM EDT
The ‘search for a magic bullet has faded’ in cancer immunotherapy. Here’s what’s next
Max Gelman
The two best-selling checkpoint inhibitors — Merck’s Keytruda and Bristol Myers Squibb’s Opdivo — are now approaching their patent cliffs. And the biopharma industry is coming to …
Eliminating KRAS: Why targeted protein degraders could redefine what’s possible in cancer
Ahead of ASCO, all eyes on pancreatic cancer
Cancer is changing. Is pharma marketing changing with it?
Europe's CHMP gives thumbs up to AZ's breast cancer drug after thumbs down from FDA adcomm
AstraZeneca, Daiichi beat Gilead to first-line TNBC with FDA nod for Datroway
Outlook moves toward potential US nod for thrice-snubbed eye drug with FDA appeal win
Merck-Kelun ADC outperforms Keytruda in trial, a closely watched Parkinson’s drug fails, and more biotech news from The Readout
Drugmakers are exploring a variety of approaches to treat head and neck cancers, from bispecific antibodies that target both PD-1…
Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck,…
By Moitreyee Chatterjee-Kishore, Ph.D., MBA, Head of Oncology Development, Astellas Pharma Inc. | How targeted protein degraders…
Two of ivonescimab’s biggest competitors are releasing new data in Chicago: pumitamig, from BioNTech and Bristol Myers Squibb;…
